The purpose of this study is to assess the immunogenicity and safety of the Infanrix hexa booster dose given at 12-18 months of age to infants who received primary vaccination at 6-12 weeks. All infants in this booster study were born to pregnant women who participated in the study 116945 [DTPA (BOOSTRIX)-047].